A collaboration to identify technologies with lifesaving potential
PATH and Merck for Mothers are collaborating on a three-year, $3.5 million effort to identify innovations with the greatest potential to help save women’s lives during pregnancy and childbirth. This unique alliance brings together product developers, maternal health experts, and business strategists to evaluate and advance high-impact technologies designed for low-resource settings.
Merck for Mothers is a ten-year initiative to reduce maternal mortality around the world. With funding from Merck for Mothers, PATH led a rigorous evaluation of nearly 50 health technologies that can help protect women from the two leading causes of maternal death: postpartum hemorrhage (excessive bleeding after birth) and preeclampsia/eclampsia (hypertensive disorders of pregnancy).
PATH developed a systematic evaluation tool to help identify five types of technologies with especially high potential for reducing maternal deaths:
- Technologies that can make it easier to administer oxytocin, a drug to reduce postpartum bleeding.
- The uterine balloon tamponade, a device to control severe postpartum bleeding.
- Simplified dosing of magnesium sulfate, an effective drug to prevent and treat severe preeclampsia and eclampsia.
- Improved proteinuria tests to detect preeclampsia.
- Blood pressure measurement devices to diagnose preeclampsia.
The tool and technology assessments can help guide donors, researchers, and others in prioritizing maternal health innovations with the greatest potential to save women’s lives.
- “Forty ideas to save mothers’ lives” on the PATH blog.
- Press release announcing the partnership.
- Our work on the maternal health technology assessment project.
- Merck for Mothers: global partners.
To learn more about PATH’s corporate partnerships, please email email@example.com.